| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $786K | -11.7% | +42.4% |
| SG&A Expense | $831K | -24.1% | +2.7% |
| Operating Income | -$1.6M | +18.6% | -18.8% |
| Net Income | -$1.6M | +18.3% | -7.8% |
| EPS (Basic) | -$1.01 | +28.4% | -531.3% |
| EPS (Diluted) | -$1.01 | +28.4% | -531.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.1M | -30.6% | -46.4% |
| Current Assets | $3.4M | -29.4% | -48.9% |
| Total Assets | $4.9M | -23.6% | -41.5% |
| Current Liabilities | $1.1M | +10.4% | +9.5% |
| Total Liabilities | $1.2M | +7.6% | +0.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.6M | — | — |
| Capital Expenditures | $306K | — | — |
| Investing Cash Flow | -$306K | — | — |
| Financing Cash Flow | $3.4M | — | — |
| Free Cash Flow | -$4.9M | — | — |
| $3.7M |
| -30.2% |
| -48.5% |